Axitinib: new hope for cancer treatment

Axitinib is suitable for the treatment of advanced renal cell carcinoma after failure of a previous systemic therapy. Its highly selective vascular epidermal growth factor receptor inhibitory ability brings a new treatment option to tumor patients. It achieves effective control of tumor growth by precisely inhibiting the blood supply of tumor cells.

Axitinib has a unique mechanism of action. It can block the activity of tyrosine kinase receptors and vascular endothelial growth factor receptors, thereby inhibiting the proliferation and differentiation of tumor cells. This mechanism is of vital significance in curbing tumor growth and brings significant therapeutic benefits to tumor patients.

In the treatment of kidney cancer, colorectal cancer, gastric cancer and other cancers, axitinib has shown excellent efficacy. Especially in advanced patients, it can significantly extend patients' survival, reduce their pain, and improve their quality of life. In addition, axitinib is often used in combination with chemotherapy drugs to enhance the therapeutic effect and bring more hope to patients.

However, like all medicines, axitinib carries certain risks. During use, we need to pay close attention to whether the patient has adverse reactions such as bleeding, ulceration, perforation, increased blood pressure, bone marrow suppression, liver and kidney function damage, etc. Once these abnormal symptoms are discovered, you should communicate with your doctor immediately to adjust the treatment plan.

In terms of medication, the recommended starting oral dose of axitinib is 5 mg twice daily. However, this dosage is not set in stone, and doctors will adjust the dosage based on the patient's safety and tolerance. When taking the medicine, patients should swallow the tablet whole and take it with food or on an empty stomach. The time interval between two daily doses should be maintained at approximately 12 hours to ensure stable release of the drug in the body.

Axitinib is undoubtedly a treatment option worth trying for adult patients with advanced renal cell carcinoma (RCC) who have failed previous treatment with tyrosine kinase inhibitors or cytokines. In addition, patients with liver and kidney dysfunction should also adjust their medication regimen under the guidance of a doctor to ensure the safety and effectiveness of treatment.

In my country, axitinib is already available for purchase and is also recognized by medical insurance. Each box of original medicine sold in China contains28 tablets of 5 mg are priced at about 6,000 yuan, and after medical insurance reimbursement, it only costs about 2,000 yuan. However, the specific reimbursement ratio will vary depending on the region. It is recommended to consult the local medical insurance department for detailed consultation. In addition, the price of axitinib with the same specifications in overseas markets is about 6,000 yuan. It is worth mentioning that Bangladesh Bikang Pharmaceutical has also launched a generic version of axitinib, with a price of only 1,800 yuan for 5 mg and 60 tablets.

In summary, axitinib, as a targeted anti-tumor drug, brings new hope to cancer patients with its significant therapeutic effect. However, during use, we still need to strictly follow medical instructions, monitor adverse reactions, and adjust the medication regimen in a timely manner to ensure patient safety.